Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Note 13 - Collaborative Agreements (Details Textual) - USD ($) $ in Thousands			12 Months Ended
	Dec. 14, 2021	Nov. 04, 2021	Dec. 31, 2021	Dec. 31, 2022	Jun. 13, 2018
Stock Issued During Period, Value, Licensing Fee			$ 7,500
CrystalGenomics [Member]
Collaborative Agreement, Milestone Payment				$ 16,000
Collaborative Agreement, Regulatory Milestone				$ 44,000
HM43239 [Member]
License Fee, Total		$ 12,500
Payments for License Fee		5,000
Stock Issued During Period, Value, Licensing Fee	$ 7,500	$ 7,500
Stock Issued During Period, Shares, Licensing Fees (in shares)	3,235,548	3,235,548
Clinical Development and Global Regulatory Milestone, First Indication		$ 64,500
Clinical Development and Global Regulatory Milestone, Second Indication		34,000
Clinical Development and Global Regulatory Milestone, Third Indication		29,000
Global Sales Milestone		$ 280,000
Exclusive License to CG806 in China, Development Milestones [Member] \| CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone					$ 6,000
Exclusive License to CG806 in China, Regulatory Milestones [Member] \| CrystalGenomics [Member]
Collaborative Agreement, Regulatory Milestone					$ 20,000